In vitro Activity of Fluoroquinolones, Vancomycin, and Gentamicin Against Methicillin-Resistant Staphylococcus aureus Ocular Isolates

Re-evaluation of in vitro activity of primycin against prevalent multiresistant bacteria

“…For 331 example, our data on susceptibility of MRSA isolates to ofloxacin, gentamicin, and 332 vancomycin make almost perfect match with results of Kotlus et al (2006). Our vancomycin 333 MIC values were in accordance with surveillance data (Draghi et al, 2008), even concerning 334 the slightly higher MIC values against CNS, especially MR-CNS compared to S. aureus 335 isolates.…”

Endoftalmites bacterianas com culturas positivas: uma revisão de 6 anos

“…O perfil de sensibilidade antibiótica foi avaliado para 14 microrganismos gram-positivos e a sensibilidade para gatifloxacina e moxifloxacina foi de 38% (30) . Outro estudo recente também demonstrou relativo aumento de resistência in vitro à fluoroquinolonas em Staphylococcus aureus meticilina-resistentes (MRSA) isolados de infecções oculares (37) . Em nosso estudo, as amostras avaliadas até o ano de 2005 apresentaram 100% de sensibilidade à gatifloxacina e moxifloxacina.…”

“…Foi demonstrado que entre os MRSA isolados de endoftalmite avaliados quanto à sensibilidade às fluoroquinolonas, 71,0% apresentaram resistentes à gatifloxacina e 68,0% à moxifloxacina. Além disso, entre os MRSA isolados de outros sítios infecciosos por esse mesmo hospital, no ano de 2005, 87,0% e 82,0% dos isolados foram resistentes à gatifloxacina e moxifloxacina, respectivamente (37) .…”

Postantibiotic Effects and Bactericidal Activities of Levofloxacin and Gatifloxacin at Concentrations Simulating Those of Topical Ophthalmic Administration against Fluoroquinolone-Resistant and Fluoroquinolone-Sensitive Methicillin-Resistant Staphylococcus aureus Strains

“…The prevalence of levofloxacin (LVX) resistance in MRSA strains isolated from patients with ocular infections is 80 to 90% in Japan and the United States (12,14,17). Topical treatments may have selected for strains with high-level fluoroquinolone resistance (1,8,10,14,17), which is associated with multiple mutations in the quinolone resistance-determining regions (QRDRs) of MRSA strains isolated at ophthalmologic clinics (10).…”

“…The prevalence of levofloxacin (LVX) resistance in MRSA strains isolated from patients with ocular infections is 80 to 90% in Japan and the United States (12,14,17). Topical treatments may have selected for strains with high-level fluoroquinolone resistance (1,8,10,14,17), which is associated with multiple mutations in the quinolone resistance-determining regions (QRDRs) of MRSA strains isolated at ophthalmologic clinics (10). Although topical fluoroquinolone eye drops contain much higher concentrations (0.3 to 1.5%; equivalent to 3,000 to 15,000 g/ml) than their MICs even against strains with high-level fluoroquinolone resistance, the antibiotic concentrations in tear films decline rapidly (by about 1/100 at 30 min) (31), and treatment failures have been noted (6,33).…”